Shares of Theravance (NASDAQ:THRX), a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC (NYSE:GSK) released disappointing clinical news.
Are the shares a buy after the fall? See the presentation below for details.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.